Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zolucatetide · FOG-001

Peptide · Inhibitor of beta-catenin (CTNNB1) · developed by Parabilis Medicines

Phase 1/2 Most advanced trial
PBLS Developer
1 Registered trials

What is Zolucatetide?

Zolucatetide (FOG-001) is a conformationally stabilized alpha-helical polypeptide that penetrates cells and binds beta-catenin, preventing its interaction with the transcription factor TCF. This blocks transcription of Wnt target genes. It is studied in colorectal, prostate, endometrial and hepatocellular cancers, desmoid tumors and other solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FOG-001
Drug type
Peptide
Targets
beta-catenin (CTNNB1)
Mechanism
Inhibitor of beta-catenin (CTNNB1)
Pathways
Wnt/beta-catenin signaling, TCF-mediated transcription of Wnt target genes, tumor microenvironment immunosuppression
Therapy area
Oncology
Developer
Parabilis Medicines, Inc. (PBLS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
GFP3KA6HMQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05919264 Phase 1/2 Cancer Recruiting PBLS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adamantinomatous CraniopharyngiomaCancerColorectal CancerDesmoidEndometrial CarcinomaFamilial Adenomatous Polyposis (FAP)HCCLocally Advanced Solid TumorMetastatic CancerMetastatic Castration-resistant Prostate CancerMicrosatellite Instability-High Colorectal CancerMicrosatellite Stable Colorectal CancerProstate CancerSolid Tumor

Other drugs acting on CTNNB1

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PBLS page.

Follow PBLS, the company behind Zolucatetide

See PBLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PBLS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.